Cue Biopharma (CUE) Other financing activities (2017 - 2025)
Cue Biopharma (CUE) posted Other financing activities of $749000.0 for Q4 2025, down 25.17% sequentially from $1.0 million in Q3 2025, and up 1214.04% YoY from $57000.0 in Q4 2024.
Cue Biopharma (CUE) Other financing activities (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Other financing activities for 9 years, with the latest figure at $749000.0 in Q4 2025.
- Quarterly Other financing activities rose 1214.04% year-over-year to $749000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (down 26.65% YoY) and the FY2025 annual result came in at $2.5 million, down 26.65% from the prior year.
- Other financing activities slipped to $749000.0 in Q4 2025 per CUE's latest filing, from $1.0 million in the prior quarter.
- Over five years, Other financing activities peaked at $16.6 million in Q3 2022 and troughed at -$8.3 million in Q3 2021.
- A 5-year average of $3.8 million and a median of $960000.0 in 2021 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 2452.78% in 2021, down 114.92% in 2021.
- Over 5 years, Other financing activities stood at $15.3 million in 2021, then rose by 8.32% to $16.6 million in 2022, then slumped by 65.16% to $5.8 million in 2023, then slumped by 99.01% to $57000.0 in 2024, then soared by 1214.04% to $749000.0 in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered $749000.0, $1.0 million, and $752000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 749,000.00 |
| Dec 31, 2025 | 749,000.00 |
| Sep 30, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | 752,000.00 |
| Jun 30, 2025 | 752,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Mar 31, 2024 | 3.35 Mn |
| Mar 31, 2024 | 3.35 Mn |
| Dec 31, 2023 | 5.78 Mn |
| Dec 31, 2023 | 5.78 Mn |
| Sep 30, 2023 | 7.13 Mn |
| Sep 30, 2023 | 7.13 Mn |
| Jun 30, 2023 | 85,000.00 |
| Jun 30, 2023 | 85,000.00 |
| Mar 31, 2023 | 388,000.00 |
| Mar 31, 2023 | 388,000.00 |
| Sep 30, 2022 | 16.60 Mn |
| Sep 30, 2022 | 16.60 Mn |